Kiromic BioPharma, Inc.
KRBPQ
$0.0615
-$0.083-57.44%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.90% | -23.46% | -29.53% | -39.10% | -42.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.23% | 8.55% | -8.41% | -28.93% | -35.92% |
| Operating Income | -19.23% | -8.55% | 8.41% | 28.93% | 35.92% |
| Income Before Tax | -28.40% | -7.60% | 29.47% | 33.27% | 39.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.40% | -7.60% | 29.47% | 33.27% | 39.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.40% | -7.60% | 29.47% | 33.27% | 39.68% |
| EBIT | -19.23% | -8.55% | 8.41% | 28.93% | 35.92% |
| EBITDA | -21.57% | -9.54% | 9.40% | 31.82% | 39.82% |
| EPS Basic | 72.09% | 52.25% | 74.54% | 76.15% | 78.07% |
| Normalized Basic EPS | 7.52% | 35.89% | 58.79% | 63.02% | 65.88% |
| EPS Diluted | 72.09% | 52.25% | 74.54% | 76.15% | 78.07% |
| Normalized Diluted EPS | 7.52% | 35.89% | 58.79% | 63.02% | 65.88% |
| Average Basic Shares Outstanding | 34.52% | 51.07% | 72.11% | 90.28% | 101.45% |
| Average Diluted Shares Outstanding | 34.52% | 51.07% | 72.11% | 90.28% | 101.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |